| ID Source | ID |
|---|---|
| PubMed CID | 2794718 |
| CHEMBL ID | 20724 |
| CHEBI ID | 156055 |
| SCHEMBL ID | 2001103 |
| Synonym |
|---|
| HMS1696K09 |
| EN300-26163 |
| BB 0219203 |
| 3-imidazol-1-yl-propionic acid |
| 1h-imidazole-1-propanoic acid |
| 18999-45-6 |
| EC-000.1978 |
| STK392438 |
| 3-(1h-imidazol-1-yl)propanoic acid , |
| CHEMBL20724 , |
| AKOS000263943 |
| CHEBI:156055 |
| 3-imidazol-1-ylpropanoic acid |
| FT-0691080 |
| A4192 |
| 3-(1h-imidazol-1-yl)propanoic acid;3-(1-imidazolyl)propanoic acid |
| 3-imidazol-1-yl-propionicacid |
| BBL012376 |
| PS-3735 |
| AB12684 |
| SCHEMBL2001103 |
| 3(1h-imidazol-1-yl)propanoic acid |
| 3-(imidazol-1-yl)-propionic acid |
| VSFNAZLYGOOSEY-UHFFFAOYSA-N |
| 3-(1-imidazolyl)propionic acid |
| 3-(1-imidazolyl)propanoic acid |
| mfcd02731119 |
| SY024292 |
| AC-26473 |
| DTXSID80383348 |
| 3-imidazol-1-yl-propionic acid, aldrichcpr |
| CS-W002976 |
| bdbm50026405 |
| Z53111117 |
| J-012268 |
| BCP11410 |
| 3-chloro-2,2,3-trimethylbutane |
| 3-(1-imidazolyl)propanoicacid |
| Role | Description |
|---|---|
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| imidazolyl carboxylic acid | Any member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium- and chloride-dependent GABA transporter 2 | Mus musculus (house mouse) | IC50 (µMol) | 501.1870 | 1.4125 | 5.2683 | 8.1283 | AID595474 |
| Sodium- and chloride-dependent GABA transporter 3 | Mus musculus (house mouse) | IC50 (µMol) | 25.7040 | 1.5488 | 3.6761 | 8.1283 | AID595475 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID595482 | Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT2 | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID595477 | Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID94678 | In vivo blood glucose was determined in obese, hyperglycemic, hyperinsulinemic, insulin-resistant KKAy mice after a dose of 500 mg/kg for 4 days | 2001 | Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8 | Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent. |
| AID595475 | Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID595509 | Selectivity ratio of pIC50 for mouse GAT3 topIC50 for mouse GAT1 | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID595474 | Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID595476 | Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID595483 | Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT4 | 2011 | European journal of medicinal chemistry, May, Volume: 46, Issue:5 | Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||